Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
Regeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.
Regeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.
comments(0)
5-min edit window · permanent after that